The Democratic Republic of Congo (DRC) is grappling with an unprecedented and rapidly expanding outbreak of Ebola caused by the Bundibugyo virus (BVD). This health emergency has escalated to become the largest Ebola disease outbreak ever recorded in the country, marked by a distressing number of cases and significant challenges to control its spread. ## Understanding Bundibugyo Virus Disease Bundibugyo virus disease is a severe, often fatal, illness caused by the Bundibugyo virus, which belongs to the same family as other Ebola viruses. It is considered a zoonotic disease, meaning it originates in animals and can spread to humans. Scientists suspect fruit bats are the natural hosts, carrying the virus without showing symptoms. Humans typically contract BVD through close contact with the blood or other bodily fluids of infected wild animals, such as bats or non-human primates, or by handling contaminated carcasses. Once a person is infected, the virus can spread from person to person through direct contact with blood, secretions, organs, or other bodily fluids of an infected individual, or from contact with surfaces and materials contaminated with these fluids. This transmission risk is significantly higher in healthcare settings where proper infection prevention and control (IPC) measures are lacking, and during unsafe burial practices that involve direct contact with the deceased. The incubation period, or the time from infection to the appearance of symptoms, can range from two to 21 days. Crucially, individuals are not infectious until they start showing symptoms. Early signs like fever, fatigue, muscle pain, headache, and sore throat are non-specific, making early diagnosis challenging and potentially delaying crucial interventions. As the disease progresses, patients can develop severe gastrointestinal issues, organ failure, and in some instances, internal and external bleeding. Historically, BVD outbreaks have shown high death rates, ranging from 30% to 50% in past events in Uganda and the DRC. ## The Growing Challenge in Democratic Republic of Congo The current Bundibugyo virus outbreak in the DRC is in a phase of intense and widespread transmission. As of mid-August 2026, a staggering 4665 confirmed cases have been reported within the DRC, leading to 2184 deaths, which translates to a case fatality ratio (CFR), or death rate, of 46.8%. This means nearly half of all confirmed patients have succumbed to the disease. The outbreak initially surfaced in the Mongbwalu health zone within Ituri Province but has since expanded dramatically, now affecting 54 health zones across six provinces: Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo, and Bas-Uélé. Ituri province remains the epicenter, accounting for a vast majority of cases and deaths. Disturbingly, the most recent reporting week saw the highest weekly numbers of both new cases and deaths, underscoring the rapid acceleration of the epidemic. The virus has also taken a toll on healthcare workers, with at least 155 infections and 45 deaths, highlighting the inherent risks and persistent challenges in maintaining robust infection control in healthcare settings outside specialized treatment centers. ## Why This Outbreak is So Difficult to Control Efforts to contain this BVD outbreak are severely hampered by a complex web of challenges. The DRC is simultaneously battling a severe humanitarian crisis, characterized by large-scale population displacement, significant population mobility, and limited access to essential services like healthcare, safe water, food, and shelter. This constant movement of people makes contact tracing and disease surveillance incredibly difficult. Adding to this complexity is widespread insecurity and persistent attacks on healthcare facilities and response teams. Since the declaration of a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 – a formal declaration by the World Health Organization (WHO) signifying an extraordinary public health risk – at least 12 attacks on health infrastructure have been recorded. Such incidents not only disrupt critical response activities but also deter patients from seeking timely care, increasing the risk of undetected transmission within communities. These deeply entrenched issues necessitate a response that is not only medically sound but also deeply rooted in community engagement and led by trusted local authorities. ## Regional and International Impact While the DRC bears the brunt of the crisis, neighboring Uganda remains at high risk of re-introduction due to ongoing transmission across their shared border and continuous population movement. Uganda has reported 20 confirmed cases and two deaths, and although its most recent imported case has been discharged, a 42-day enhanced monitoring period is still underway. Health authorities in Uganda are maintaining heightened surveillance to quickly detect and respond to any new cases. Beyond the African continent, a few imported cases have been reported in Europe. France successfully managed an imported case, with no secondary transmission reported after the patient's discharge. Similarly, two cases diagnosed in the DRC were successfully treated in Germany. These instances underscore the importance of robust international preparedness and response mechanisms. ## The Public Health Response in Action In response to this escalating crisis, national authorities in the DRC, supported by the WHO and various international partners, are implementing extensive public health measures. These efforts are guided by a comprehensive continental preparedness and response plan, a six-month framework designed to coordinate and strengthen all aspects of the outbreak response. Key pillars include enhancing emergency coordination, bolstering disease surveillance to quickly identify new cases, increasing laboratory testing and diagnostic capabilities, implementing stringent infection prevention and control protocols, providing expert clinical care, fostering strong community engagement, supporting research, ensuring robust logistics, and maintaining essential health services. A substantial scaling up of these activities is currently underway across all affected and at-risk areas. High-level missions by leaders from WHO and Africa CDC have emphasized surveillance and closer community collaboration as top priorities. Expansion of treatment centers and extensive training for healthcare workers are also critical components of the strategy. ## Advancements in Treatment and Prevention The global health community is actively pursuing both treatments and potential vaccines for Bundibugyo virus disease. While no approved vaccines or specific treatments *currently* exist solely for BVD, significant progress is being made through clinical trials. The WHO has convened technical advisory groups, including the Strategic Advisory Group of Experts on Immunization (SAGE), to evaluate candidate vaccines and therapies. Notably, the WHO Technical Advisory Group recently recommended that Ervebo, the only licensed Ebola vaccine (which targets the Zaire ebolavirus), be prioritized for inclusion in a randomized clinical trial specifically for the ongoing Bundibugyo outbreak in the DRC. This is a crucial step to determine if this existing vaccine can offer protection against the Bundibugyo strain. WHO is actively collaborating with partners to launch this trial as swiftly as possible. In parallel, a clinical trial for effective BVD treatments, known as the PARTNERS trial, commenced enrollment on July 2nd. This trial is currently operational in three clinical management facilities in Ituri province and has already enrolled over 100 confirmed cases, striving to identify life-saving therapies. ## Global Risk Assessment and WHO Advice The WHO periodically reassesses the risk associated with the BVD outbreak. The most recent assessment identifies the risk within the DRC as very high due to continuous transmission and the rapid geographical expansion of the virus. Uganda and other countries sharing land borders with affected nations are categorized as high risk, primarily due to sustained population mobility, cross-border trade, mining activities, and varied capacities in public health response. For the rest of the African region and globally, the risk is currently assessed as low. Based on the available data, the WHO maintains its advice against imposing any restrictions on international travel or trade with the affected countries, emphasizing that such measures are not effective in controlling the spread of the virus and can negatively impact essential humanitarian efforts. Instead, the focus remains on implementing coordinated outbreak control, strengthening cross-border collaboration, and sustaining robust surveillance and preparedness measures to prevent further regional spread and ensure an effective global public health response. Rapid recognition of cases, timely testing, and optimized supportive care are crucial to reduce mortality and foster community trust in the response efforts.